Brief: Zydus Lifesciences Enters Settlement Agreement With Astellas Over Myrbetriq
12/02/2026 03:02
Feb 12 (Reuters) - Zydus Lifesciences Ltd ZYDU.NS: ZYDUS LIFESCIENCES - ENTERS SETTLEMENT AGREEMENT WITH ASTELLAS OVER MYRBETRIQ ZYDUS LIFESCIENCES - TO PAY ASTELLAS USD 120 MILLION ZYDUS LIFESCIENCES - TO PAY LICENSING FEE ON GENERIC MIRABEGRON ZYDUS LIFESCIENCES - SETTLEMENT CONCLUDES LITIGATIONS, ZYDUS TO MARKET GENERIC MIRABEGRON Source text: ID:nBSE4lWKCb Further company coverage: ZYDU.NS ((reuters.briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn